Vaxart, Inc. (VXRT)
USD 0.29
(-12.84%)
USD 0.29
(-12.84%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -83.34 Million USD | 27.26% |
| 2022 | -114.58 Million USD | -57.5% |
| 2021 | -72.75 Million USD | -141.14% |
| 2020 | -30.17 Million USD | -91.13% |
| 2019 | -15.78 Million USD | 27.45% |
| 2018 | -21.75 Million USD | -138.68% |
| 2017 | -9.11 Million USD | 66.85% |
| 2016 | -27.5 Million USD | -9.13% |
| 2015 | -25.2 Million USD | -29.23% |
| 2014 | -19.5 Million USD | -69.57% |
| 2013 | -11.5 Million USD | 47.96% |
| 2012 | -22.1 Million USD | -126.39% |
| 2011 | -9.76 Million USD | -714.86% |
| 2010 | -1.19 Million USD | 93.34% |
| 2009 | -17.97 Million USD | 28.01% |
| 2008 | -24.97 Million USD | 44.42% |
| 2007 | -44.93 Million USD | 26.73% |
| 2006 | -61.32 Million USD | 50.0% |
| 2005 | -122.64 Million USD | -135.64% |
| 2004 | -52.04 Million USD | -303.29% |
| 2003 | -12.9 Million USD | -451.63% |
| 2002 | 3.67 Million USD | -96.86% |
| 2001 | 117.01 Million USD | 3167.55% |
| 2000 | 3.58 Million USD | -38.26% |
| 1999 | 5.8 Million USD | 514.29% |
| 1998 | -1.4 Million USD | 75.44% |
| 1997 | -5.7 Million USD | -150.89% |
| 1996 | 11.2 Million USD | 216.67% |
| 1995 | -9.6 Million USD | -155.17% |
| 1994 | 17.4 Million USD | 104.71% |
| 1993 | 8.5 Million USD | 347.37% |
| 1992 | 1.9 Million USD | -42.42% |
| 1991 | 3.3 Million USD | 0.0% |
| 1990 | 3.3 Million USD | 94.12% |
| 1989 | 1.7 Million USD | 21.43% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -24.07 Million USD | -42.43% |
| 2024 Q2 | -16.25 Million USD | 32.46% |
| 2023 Q3 | -17.82 Million USD | 22.69% |
| 2023 Q1 | -25.57 Million USD | 17.88% |
| 2023 Q2 | -23.05 Million USD | 9.85% |
| 2023 Q4 | -16.9 Million USD | 5.17% |
| 2023 FY | -83.34 Million USD | 27.26% |
| 2022 Q1 | -24.77 Million USD | -2.32% |
| 2022 Q4 | -31.13 Million USD | -5.82% |
| 2022 Q3 | -29.42 Million USD | -0.61% |
| 2022 Q2 | -29.24 Million USD | -18.05% |
| 2022 FY | -114.58 Million USD | -57.5% |
| 2021 Q1 | -15.51 Million USD | -16.09% |
| 2021 Q2 | -15.77 Million USD | -1.7% |
| 2021 FY | -72.75 Million USD | -141.14% |
| 2021 Q4 | -24.21 Million USD | -40.37% |
| 2021 Q3 | -17.25 Million USD | -9.36% |
| 2020 Q1 | -694 Thousand USD | 87.66% |
| 2020 Q2 | -8.52 Million USD | -1128.53% |
| 2020 Q4 | -13.36 Million USD | -76.06% |
| 2020 Q3 | -7.58 Million USD | 10.99% |
| 2020 FY | -30.17 Million USD | -91.13% |
| 2019 Q1 | -448 Thousand USD | 89.3% |
| 2019 Q2 | -4.99 Million USD | -1015.4% |
| 2019 Q3 | -4.71 Million USD | 5.66% |
| 2019 Q4 | -5.62 Million USD | -19.35% |
| 2019 FY | -15.78 Million USD | 27.45% |
| 2018 Q4 | -4.18 Million USD | 28.81% |
| 2018 FY | -21.75 Million USD | -138.68% |
| 2018 Q1 | -3.91 Million USD | -35.0% |
| 2018 Q2 | -7.77 Million USD | -98.6% |
| 2018 Q3 | -5.88 Million USD | 24.37% |
| 2017 FY | -9.11 Million USD | 66.85% |
| 2017 Q3 | -5 Million USD | 10.71% |
| 2017 Q4 | -2.9 Million USD | 42.0% |
| 2017 Q2 | -5.6 Million USD | -47.37% |
| 2017 Q1 | -3.8 Million USD | 55.81% |
| 2016 FY | -27.5 Million USD | -9.13% |
| 2016 Q4 | -8.6 Million USD | 10.42% |
| 2016 Q3 | -9.6 Million USD | -43.28% |
| 2016 Q2 | -6.7 Million USD | -28.85% |
| 2016 Q1 | -5.2 Million USD | 20.0% |
| 2015 FY | -25.2 Million USD | -29.23% |
| 2015 Q4 | -6.5 Million USD | 2.99% |
| 2015 Q1 | 1.1 Million USD | -82.81% |
| 2015 Q2 | -20 Million USD | -1918.18% |
| 2015 Q3 | -6.7 Million USD | 66.5% |
| 2014 Q3 | -7 Million USD | 33.33% |
| 2014 Q1 | 3.2 Million USD | 3300.0% |
| 2014 Q4 | 6.4 Million USD | 191.43% |
| 2014 FY | -19.5 Million USD | -69.57% |
| 2014 Q2 | -10.5 Million USD | -428.13% |
| 2013 Q2 | -6.42 Million USD | -21526.67% |
| 2013 FY | -11.5 Million USD | 47.96% |
| 2013 Q4 | -100 Thousand USD | 97.56% |
| 2013 Q3 | -4.1 Million USD | 36.22% |
| 2013 Q1 | 30 Thousand USD | 100.38% |
| 2012 FY | -22.1 Million USD | -126.39% |
| 2012 Q2 | -2.87 Million USD | -32.92% |
| 2012 Q3 | -4.11 Million USD | -43.23% |
| 2012 Q1 | -2.16 Million USD | -7.67% |
| 2012 Q4 | -7.82 Million USD | -90.02% |
| 2011 Q4 | -2 Million USD | 59.31% |
| 2011 Q1 | 1.87 Million USD | 129.33% |
| 2011 Q2 | -4.68 Million USD | -350.51% |
| 2011 Q3 | -4.93 Million USD | -5.33% |
| 2011 FY | -9.76 Million USD | -714.86% |
| 2010 Q3 | 3.27 Million USD | 193.95% |
| 2010 FY | -1.19 Million USD | 93.34% |
| 2010 Q4 | -6.37 Million USD | -294.72% |
| 2010 Q2 | -3.48 Million USD | -164.67% |
| 2010 Q1 | 5.39 Million USD | 221.53% |
| 2009 FY | -17.97 Million USD | 28.01% |
| 2009 Q1 | -6.85 Million USD | -39.35% |
| 2009 Q4 | 1.67 Million USD | 123.95% |
| 2009 Q2 | -5.79 Million USD | 15.48% |
| 2009 Q3 | -7 Million USD | -20.83% |
| 2008 Q4 | -4.92 Million USD | 9.59% |
| 2008 Q3 | -5.44 Million USD | 13.22% |
| 2008 Q2 | -6.27 Million USD | 24.79% |
| 2008 Q1 | -8.33 Million USD | 6.77% |
| 2008 FY | -24.97 Million USD | 44.42% |
| 2007 Q3 | -16.43 Million USD | -48.5% |
| 2007 Q4 | -8.94 Million USD | 45.57% |
| 2007 Q1 | -11.12 Million USD | -35.56% |
| 2007 Q2 | -11.06 Million USD | 0.57% |
| 2007 FY | -44.93 Million USD | 26.73% |
| 2006 Q4 | -8.2 Million USD | 49.95% |
| 2006 FY | -61.32 Million USD | 50.0% |
| 2006 Q3 | -16.4 Million USD | -16.99% |
| 2006 Q2 | -14.01 Million USD | 10.33% |
| 2006 Q1 | -15.63 Million USD | 71.78% |
| 2005 Q2 | -28.12 Million USD | -22.46% |
| 2005 FY | -122.64 Million USD | -135.64% |
| 2005 Q1 | -22.96 Million USD | -26.85% |
| 2005 Q4 | -55.39 Million USD | -142.08% |
| 2005 Q3 | -22.88 Million USD | 18.63% |
| 2004 Q4 | -18.1 Million USD | -99.83% |
| 2004 Q3 | -9.05 Million USD | -0.14% |
| 2004 Q1 | -3.42 Million USD | 72.96% |
| 2004 Q2 | -9.04 Million USD | -163.96% |
| 2004 FY | -52.04 Million USD | -303.29% |
| 2003 FY | -12.9 Million USD | -451.63% |
| 2003 Q4 | -12.67 Million USD | -460.2% |
| 2003 Q3 | 3.51 Million USD | 182.39% |
| 2003 Q2 | -4.27 Million USD | -922.74% |
| 2003 Q1 | 519 Thousand USD | -56.68% |
| 2002 Q4 | 1.19 Million USD | 17.8% |
| 2002 Q1 | 329 Thousand USD | -94.6% |
| 2002 Q2 | 1.12 Million USD | 242.25% |
| 2002 Q3 | 1.01 Million USD | -9.68% |
| 2002 FY | 3.67 Million USD | -96.86% |
| 2001 FY | 117.01 Million USD | 3167.55% |
| 2001 Q4 | 6.08 Million USD | -94.35% |
| 2001 Q3 | 107.65 Million USD | 5299.0% |
| 2001 Q2 | 1.99 Million USD | 56.51% |
| 2001 Q1 | 1.27 Million USD | 144.25% |
| 2000 Q4 | -2.87 Million USD | -4.46% |
| 2000 FY | 3.58 Million USD | -38.26% |
| 2000 Q1 | 1.52 Million USD | -36.38% |
| 2000 Q2 | 1.95 Million USD | 28.29% |
| 2000 Q3 | -2.75 Million USD | -240.68% |
| 1999 FY | 5.8 Million USD | 514.29% |
| 1999 Q4 | 2.4 Million USD | 700.0% |
| 1999 Q3 | 300 Thousand USD | -88.88% |
| 1999 Q1 | 423 Thousand USD | 5.75% |
| 1999 Q2 | 2.69 Million USD | 537.83% |
| 1998 FY | -1.4 Million USD | 75.44% |
| 1998 Q1 | -2.1 Million USD | 69.12% |
| 1998 Q2 | 200 Thousand USD | 109.52% |
| 1998 Q4 | 400 Thousand USD | 33.33% |
| 1998 Q3 | 300 Thousand USD | 50.0% |
| 1997 Q1 | 2.9 Million USD | -36.96% |
| 1997 Q3 | -4.9 Million USD | -248.48% |
| 1997 Q4 | -6.8 Million USD | -38.78% |
| 1997 FY | -5.7 Million USD | -150.89% |
| 1997 Q2 | 3.3 Million USD | 13.79% |
| 1996 FY | 11.2 Million USD | 216.67% |
| 1996 Q2 | 2.3 Million USD | 9.52% |
| 1996 Q3 | 2 Million USD | -13.04% |
| 1996 Q4 | 4.6 Million USD | 130.0% |
| 1996 Q1 | 2.1 Million USD | 107.89% |
| 1995 Q3 | 6 Million USD | 3.45% |
| 1995 Q4 | -26.6 Million USD | -543.33% |
| 1995 Q1 | 5.3 Million USD | 3.92% |
| 1995 Q2 | 5.8 Million USD | 9.43% |
| 1995 FY | -9.6 Million USD | -155.17% |
| 1994 Q2 | 4.3 Million USD | 26.47% |
| 1994 FY | 17.4 Million USD | 104.71% |
| 1994 Q4 | 5.1 Million USD | 10.87% |
| 1994 Q1 | 3.4 Million USD | 13.33% |
| 1994 Q3 | 4.6 Million USD | 6.98% |
| 1993 Q3 | 2.2 Million USD | 15.79% |
| 1993 Q4 | 3 Million USD | 36.36% |
| 1993 Q1 | 1.3 Million USD | 333.33% |
| 1993 Q2 | 1.9 Million USD | 46.15% |
| 1993 FY | 8.5 Million USD | 347.37% |
| 1992 Q1 | 700 Thousand USD | -22.22% |
| 1992 Q4 | 300 Thousand USD | 150.0% |
| 1992 FY | 1.9 Million USD | -42.42% |
| 1992 Q2 | 1.3 Million USD | 85.71% |
| 1992 Q3 | -600 Thousand USD | -146.15% |
| 1991 Q4 | 900 Thousand USD | 28.57% |
| 1991 FY | 3.3 Million USD | 0.0% |
| 1991 Q1 | 800 Thousand USD | -11.11% |
| 1991 Q2 | 800 Thousand USD | 0.0% |
| 1991 Q3 | 700 Thousand USD | -12.5% |
| 1990 FY | 3.3 Million USD | 94.12% |
| 1990 Q4 | 900 Thousand USD | 28.57% |
| 1990 Q3 | 700 Thousand USD | -22.22% |
| 1990 Q2 | 900 Thousand USD | 28.57% |
| 1990 Q1 | 700 Thousand USD | 40.0% |
| 1989 Q4 | 500 Thousand USD | -28.57% |
| 1989 FY | 1.7 Million USD | 21.43% |
| 1989 Q1 | 13.6 Million USD | 139.31% |
| 1989 Q3 | 700 Thousand USD | 75.0% |
| 1989 Q2 | 400 Thousand USD | -97.06% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -237.2 Million USD | 64.863% |
| Alkermes plc | 414.12 Million USD | 120.126% |
| Agenus Inc. | -159.54 Million USD | 47.761% |
| Aptorum Group Limited | -10.52 Million USD | -692.021% |
| Ardelyx, Inc. | -63.27 Million USD | -31.72% |
| Dyadic International, Inc. | -8.22 Million USD | -912.754% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | -6892.198% |
| Lantern Pharma Inc. | -17.87 Million USD | -366.21% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | -314.872% |
| Novavax, Inc. | -566.51 Million USD | 85.288% |
| Janux Therapeutics, Inc. | -72.97 Million USD | -14.207% |
| Pyxis Oncology, Inc. | -82.19 Million USD | -1.4% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | -329.214% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | -689.047% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | -56.884% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 78.095% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | -242.899% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | -120.093% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 35.384% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 0.676% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -375.21% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | -89.382% |
| Clearside Biomedical, Inc. | -24.84 Million USD | -235.481% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 40.051% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 70.463% |
| AlloVir, Inc. | -181.33 Million USD | 54.036% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 59.343% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -184.869% |
| Bicycle Therapeutics plc | -189.94 Million USD | 56.121% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 51.481% |
| ChromaDex Corporation | -5.59 Million USD | -1388.605% |
| Chimerix, Inc. | -93.06 Million USD | 10.442% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -84.898% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 28.186% |
| CRISPR Therapeutics AG | -222.53 Million USD | 62.547% |
| Precision BioSciences, Inc. | -43.73 Million USD | -90.568% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 56.251% |
| Fortress Biotech, Inc. | -142.34 Million USD | 41.446% |
| Fortress Biotech, Inc. | -142.34 Million USD | 41.446% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 14.686% |
| ImmuCell Corporation | -5.74 Million USD | -1349.998% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 37.999% |
| Immix Biopharma, Inc. | -16.14 Million USD | -416.365% |
| Incyte Corporation | 620.52 Million USD | 113.432% |
| Innoviva, Inc. | 176.7 Million USD | 147.166% |
| IO Biotech, Inc. | -91.44 Million USD | 8.854% |
| Jaguar Health, Inc. | -34.29 Million USD | -143.058% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 50.955% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | 797.932% |
| ContextLogic Inc. | -328 Million USD | 74.589% |
| MiMedx Group, Inc. | 37.11 Million USD | 324.558% |
| MEI Pharma, Inc. | 14.54 Million USD | 673.147% |
| NextCure, Inc. | -67.63 Million USD | -23.227% |
| Onconetix, Inc. | -36.03 Million USD | -131.297% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | -99.806% |
| Opthea Limited | -191.84 Million USD | 56.555% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -2928.79% |
| Vaxcyte, Inc. | -468.04 Million USD | 82.192% |
| PDS Biotechnology Corporation | -43.04 Million USD | -93.627% |
| Precigen, Inc. | -88.92 Million USD | 6.271% |
| Pharming Group N.V. | -4.87 Million USD | -1608.09% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 50.185% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | -180.101% |
| PureTech Health plc | -146.19 Million USD | 42.991% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | -306.749% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 64.623% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | -242.899% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 69.582% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | -184.412% |
| Acelyrin, Inc. | -422.06 Million USD | 80.253% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | -646254.306% |
| Summit Therapeutics Inc. | -89.73 Million USD | 7.12% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | -124.873% |
| Senti Biosciences, Inc. | -92.72 Million USD | 10.116% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 27.381% |
| Elevation Oncology, Inc. | -45.44 Million USD | -83.402% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | -143.228% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | -2014.307% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | -2535.895% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | -152.406% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -880.438% |
| Wave Life Sciences Ltd. | -67.99 Million USD | -22.576% |
| Seer, Inc. | -103.46 Million USD | 19.443% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | -26.746% |
| Aadi Bioscience, Inc. | -71.93 Million USD | -15.868% |
| ESSA Pharma Inc. | -32.13 Million USD | -159.372% |
| GlycoMimetics, Inc. | -39.27 Million USD | -112.212% |
| GT Biopharma, Inc. | -13.57 Million USD | -513.929% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 61.98% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | -80.186% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 196.009% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | -46.844% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | -61.82% |
| Alzamend Neuro, Inc. | -9.93 Million USD | -738.7% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 83.473% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -1108.278% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | -64.415% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 67.901% |
| Aptose Biosciences Inc. | -52.35 Million USD | -59.193% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | -477.965% |
| Soligenix, Inc. | -7.69 Million USD | -982.718% |
| Century Therapeutics, Inc. | -146.54 Million USD | 43.126% |
| Kura Oncology, Inc. | -165.8 Million USD | 49.732% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 10.819% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | -901.887% |
| Ocean Biomedical, Inc. | -2.48 Million USD | -3258.547% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | -1185.426% |
| Autolus Therapeutics plc | -195.02 Million USD | 57.264% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 1.547% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | -13.148% |
| Eterna Therapeutics Inc. | -21.13 Million USD | -294.355% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 63.289% |
| GRI Bio, Inc. | -11.38 Million USD | -631.949% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -1745.71% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 36.47% |
| IGM Biosciences, Inc. | -263.46 Million USD | 68.365% |
| INmune Bio, Inc. | -29.74 Million USD | -180.243% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 24.651% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | -118.9% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | -421.592% |
| Entero Therapeutics, Inc. | -15.77 Million USD | -428.488% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | -36.415% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 22.484% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 69.802% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 58.983% |
| Verastem, Inc. | -92.08 Million USD | 9.488% |
| Abeona Therapeutics Inc. | -47.13 Million USD | -76.826% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 54.738% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 29.594% |
| Histogen Inc. | -10.64 Million USD | -683.116% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | -438.697% |
| Surrozen, Inc. | -45.78 Million USD | -82.06% |
| Organovo Holdings, Inc. | -15.08 Million USD | -452.479% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -1537.39% |
| Ovid Therapeutics Inc. | -59.28 Million USD | -40.595% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -62.489% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | -229.695% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | -991.952% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 51.34% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | -72.034% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | -6.575% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | -447.587% |
| Apollomics, Inc. | -54.83 Million USD | -51.999% |
| Amarin Corporation plc | -67.58 Million USD | -23.316% |
| Mesoblast Limited | -58.79 Million USD | -41.761% |
| Turnstone Biologics Corp. | -59.03 Million USD | -41.19% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 49.648% |
| Synaptogenix, Inc. | -8.31 Million USD | -902.507% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | -471.418% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 9.1% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -1639.488% |
| Monopar Therapeutics Inc. | -8.83 Million USD | -843.775% |
| Exelixis, Inc. | 170.88 Million USD | 148.774% |
| Better Therapeutics, Inc. | -38.26 Million USD | -117.832% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 46.25% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 83.882% |
| NLS Pharmaceutics AG | -11.8 Million USD | -605.908% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | -936.409% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -177.888% |
| Gritstone bio, Inc. | -154.63 Million USD | 46.1% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | -21.037% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | -386.753% |
| Avid Bioservices, Inc. | -18.67 Million USD | -346.231% |
| Insmed Incorporated | -709.62 Million USD | 88.255% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | -431.218% |
| MediWound Ltd. | -15.29 Million USD | -445.108% |
| OmniAb, Inc. | -69.41 Million USD | -20.064% |
| Alector, Inc. | -151.74 Million USD | 45.072% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 22.815% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | -59.828% |
| Zai Lab Limited | -366.57 Million USD | 77.263% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 73.689% |
| Aura Biosciences, Inc. | -84.99 Million USD | 1.934% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 66.05% |
| Immunic, Inc. | -99.22 Million USD | 16.0% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 41.78% |
| Veracyte, Inc. | -85.79 Million USD | 2.853% |
| InMed Pharmaceuticals Inc. | - USD | Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 70.425% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | -486.538% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | -1110.041% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | -343.509% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 114.405% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | -227.455% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | 314.801% |
| TG Therapeutics, Inc. | 20.63 Million USD | 503.95% |
| Galecto, Inc. | -39.9 Million USD | -108.864% |
| Calithera Biosciences, Inc. | -42.07 Million USD | -98.096% |
| Fortrea Holdings Inc. | 63.1 Million USD | 232.087% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 40.655% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | -188.618% |
| XBiotech Inc. | -37.51 Million USD | -122.199% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | -21.037% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | -24.176% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 22.76% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -224.661% |
| Theravance Biopharma, Inc. | -53.29 Million USD | -56.397% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 85.357% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | -6.185% |
| Vaxxinity, Inc. | -58.28 Million USD | -42.999% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 19.634% |
| Gain Therapeutics, Inc. | -22.25 Million USD | -274.541% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 3.551% |
| NexImmune, Inc. | -29.19 Million USD | -185.508% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | -1383.008% |
| Marker Therapeutics, Inc. | -14.58 Million USD | -471.599% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 102.059% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | -227.377% |
| Scopus BioPharma Inc. | -11.71 Million USD | -611.463% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 34.404% |
| Ainos, Inc. | -13.2 Million USD | -531.111% |
| Pluri Inc. | -22.15 Million USD | -276.149% |
| Prothena Corporation plc | -191.03 Million USD | 56.371% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 39.62% |
| Celularity Inc. | -192.28 Million USD | 56.655% |
| Rallybio Corporation | -78.93 Million USD | -5.593% |
| Cue Biopharma, Inc. | -52.14 Million USD | -59.825% |
| MeiraGTx Holdings plc | -137.06 Million USD | 39.19% |
| Omeros Corporation | -164.53 Million USD | 49.342% |
| Humacyte, Inc. | -100.04 Million USD | 16.692% |
| Immunocore Holdings plc | -59.64 Million USD | -39.729% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | -349.092% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | -240.428% |
| Blueprint Medicines Corporation | -486.27 Million USD | 82.86% |
| CalciMedica, Inc. | -21.87 Million USD | -281.015% |
| Cabaletta Bio, Inc. | -74.66 Million USD | -11.635% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 36.611% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 51.343% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 74.504% |
| Pulmatrix, Inc. | -14.74 Million USD | -465.448% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | -133.171% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 6.21% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 83.825% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | -23.384% |
| Cytokinetics, Incorporated | -496.2 Million USD | 83.203% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | -142.154% |
| Nutriband Inc. | -4.87 Million USD | -1610.761% |
| Protara Therapeutics, Inc. | -43.61 Million USD | -91.106% |
| Vor Biopharma Inc. | -126.03 Million USD | 33.87% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 101.965% |
| Evogene Ltd. | -26.39 Million USD | -215.816% |
| ProKidney Corp. | -151.52 Million USD | 44.993% |
| Applied Therapeutics, Inc. | -64.53 Million USD | -29.15% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | -983.52% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 86.277% |
| CorMedix Inc. | -48.95 Million USD | -70.243% |
| BioLineRx Ltd. | -49.69 Million USD | -67.72% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 26.999% |
| Galectin Therapeutics Inc. | -38.07 Million USD | -118.919% |
| Atai Life Sciences N.V. | -125.47 Million USD | 33.573% |
| Renovaro Biosciences Inc. | -81.63 Million USD | -2.092% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | -2.381% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 66.526% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -171.135% |
| MediciNova, Inc. | -9.9 Million USD | -741.866% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 34.047% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -1050.811% |
| GeoVax Labs, Inc. | -26.74 Million USD | -211.66% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 64.047% |
| Biomea Fusion, Inc. | -126.13 Million USD | 33.922% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 76.146% |
| Mereo BioPharma Group plc | -28.41 Million USD | -193.31% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 56.383% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 63.755% |
| Absci Corporation | -115.51 Million USD | 27.847% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | -202.124% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 26.155% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 65.582% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | -230.795% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 59.928% |
| Allakos Inc. | -196.05 Million USD | 57.488% |
| Imunon, Inc. | -21.03 Million USD | -296.316% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 24.685% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 177.69% |
| BioAtla, Inc. | -129.68 Million USD | 35.732% |
| NLS Pharmaceutics AG | -11.8 Million USD | -605.908% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -426.081% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 74.569% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | -99.595% |
| XOMA Corporation | -41.84 Million USD | -99.166% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 20.801% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 31.399% |
| aTyr Pharma, Inc. | -54.91 Million USD | -51.764% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 4.667% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 51.786% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 67.244% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | -288.274% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | -914.848% |
| Akari Therapeutics, Plc | -16.8 Million USD | -395.936% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -942416.309% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 124.69% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -1175.585% |
| UroGen Pharma Ltd. | -65.53 Million USD | -27.177% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 6.643% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -1047.554% |
| Orgenesis Inc. | -53.63 Million USD | -55.394% |
| Entera Bio Ltd. | -8.89 Million USD | -837.431% |
| GH Research PLC | -41.22 Million USD | -102.191% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | -224.206% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | -0.354% |
| Xencor, Inc. | -138.63 Million USD | 39.882% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | -1516.949% |
| Replimune Group, Inc. | -234.77 Million USD | 64.499% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | -287.821% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | -497.384% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -1175.585% |
| Portage Biotech Inc. | -18.25 Million USD | -356.621% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -1050.811% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 20.592% |
| OncoCyte Corporation | -25.13 Million USD | -231.584% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -637.267% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -627.473% |
| Purple Biotech Ltd. | 22.27 Million USD | 474.24% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | -1009.518% |
| scPharmaceuticals Inc. | -55.39 Million USD | -50.457% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | -341.043% |
| HilleVax, Inc. | -133.34 Million USD | 37.495% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | -591.734% |
| Tharimmune, Inc. | -9.45 Million USD | -781.492% |
| Genprex, Inc. | -31.07 Million USD | -168.207% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 55.712% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | -165.631% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | -10795.033% |
| Virios Therapeutics, Inc. | -5.44 Million USD | -1430.168% |
| OKYO Pharma Limited | -15.74 Thousand USD | -529096.374% |
| Savara Inc. | -60 Million USD | -38.895% |
| Curis, Inc. | -48.33 Million USD | -72.447% |
| Daré Bioscience, Inc. | -30.83 Million USD | -170.257% |
| Carmell Therapeutics Corporation | -5.21 Million USD | -1497.518% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | -1045.348% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | -205.861% |
| BeiGene, Ltd. | -1.2 Billion USD | 93.099% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -318.004% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 82.892% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 11.004% |
| Erasca, Inc. | -141.52 Million USD | 41.108% |
| bluebird bio, Inc. | -244.26 Million USD | 65.878% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -1741.119% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 142.865% |
| DBV Technologies S.A. | -76.43 Million USD | -9.047% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -1741.119% |
| Moderna, Inc. | -4.23 Billion USD | 98.034% |
| Vincerx Pharma, Inc. | -42.6 Million USD | -95.609% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | -1210.487% |
| Molecular Templates, Inc. | -10.46 Million USD | -696.36% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | -23.96% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 77.877% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 41.842% |
| Spruce Biosciences, Inc. | -51.99 Million USD | -60.304% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 46.068% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 59.954% |
| MacroGenics, Inc. | -168.24 Million USD | 50.461% |
| RenovoRx, Inc. | -11.39 Million USD | -631.371% |
| Adicet Bio, Inc. | -152.03 Million USD | 45.18% |
| Prime Medicine, Inc. | -191.29 Million USD | 56.429% |
| Aditxt, Inc. | -26.06 Million USD | -219.798% |
| Adagene Inc. | -23.71 Million USD | -251.381% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -1040.163% |
| Quantum-Si incorporated | -111.17 Million USD | 25.028% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | -163.356% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | -471.74% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 168.309% |
| SciSparc Ltd. | -5.77 Million USD | -1343.738% |
| Vericel Corporation | -6.46 Million USD | -1189.403% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -862.807% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | -260.504% |
| Generation Bio Co. | -138.56 Million USD | 39.849% |
| Astria Therapeutics, Inc. | -83.03 Million USD | -0.382% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 3.601% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 65.431% |
| Invivyd, Inc. | -207.78 Million USD | 59.887% |
| Relay Therapeutics, Inc. | -373 Million USD | 77.655% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | -788.703% |
| Spero Therapeutics, Inc. | 21.48 Million USD | 488.003% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -710.217% |
| 2seventy bio, Inc. | -216.7 Million USD | 61.539% |
| ADMA Biologics, Inc. | 21.63 Million USD | 485.295% |
| Clene Inc. | -40.54 Million USD | -105.592% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | -246.156% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | -52.104% |
| GeoVax Labs, Inc. | -26.74 Million USD | -211.66% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 76.191% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | -126.906% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | 618.424% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 19.628% |
| Finch Therapeutics Group, Inc. | -34 Million USD | -145.124% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 51.052% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 87.82% |
| Evaxion Biotech A/S | -22.19 Million USD | -275.488% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | -1.171% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 62.645% |
| Trevena, Inc. | -35.28 Million USD | -136.191% |
| Surrozen, Inc. | -45.78 Million USD | -82.06% |
| Tyra Biosciences, Inc. | -79.94 Million USD | -4.255% |
| Cingulate Inc. | -22.75 Million USD | -266.213% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | 1212.48% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -86.596% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | -912.237% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 18.732% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | -13.584% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | -34.27% |
| Clearmind Medicine Inc. | -8.74 Million USD | -853.48% |
| Kronos Bio, Inc. | -121.83 Million USD | 31.587% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | -9.385% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -2741.712% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 17.337% |
| Statera Biopharma, Inc. | -98.34 Million USD | 15.249% |
| ImmunityBio, Inc. | -362.25 Million USD | 76.992% |
| Korro Bio, Inc. | -84.53 Million USD | 1.404% |
| Kineta, Inc. | -15.72 Million USD | -430.096% |
| BioVie Inc. | -32.17 Million USD | -159.006% |
| Codexis, Inc. | -68.06 Million USD | -22.445% |
| Celularity Inc. | -192.28 Million USD | 56.655% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 62.559% |
| Celcuity Inc. | -66.23 Million USD | -25.844% |
| Virax Biolabs Group Limited | -6.49 Million USD | -1182.958% |
| Cibus, Inc. | -318.88 Million USD | 73.863% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | -93.83% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -146.268% |
| IN8bio, Inc. | -30.33 Million USD | -174.737% |
| Kodiak Sciences Inc. | -277.32 Million USD | 69.946% |
| Annexon, Inc. | -143.72 Million USD | 42.009% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 32.671% |
| Assembly Biosciences, Inc. | -64.64 Million USD | -28.928% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | -255.515% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 76.438% |
| Eyenovia, Inc. | -25.4 Million USD | -228.055% |
| Puma Biotechnology, Inc. | 32.64 Million USD | 355.352% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -1398.508% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | -5.325% |
| Arcellx, Inc. | -89.88 Million USD | 7.269% |
| Cardiff Oncology, Inc. | -45.41 Million USD | -83.535% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 39.255% |
| Regulus Therapeutics Inc. | -31.1 Million USD | -167.919% |
| Moolec Science SA | -6.65 Million USD | -1152.622% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | -36.326% |
| Geron Corporation | -193.94 Million USD | 57.025% |
| LAVA Therapeutics N.V. | -43.25 Million USD | -92.696% |
| Royalty Pharma plc | 1.49 Billion USD | 105.586% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 49.229% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -793.527% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | -280.673% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 51.247% |
| Humacyte, Inc. | -100.04 Million USD | 16.692% |
| Structure Therapeutics Inc. | -102.77 Million USD | 18.903% |
| 89bio, Inc. | -151.2 Million USD | 44.878% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | -4.012% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | -473.226% |
| Genelux Corporation | -24.16 Million USD | -244.908% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | -145.695% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 51.472% |
| Notable Labs, Ltd. | -14.65 Million USD | -468.65% |
| Liquidia Corporation | -73.38 Million USD | -13.577% |
| Mustang Bio, Inc. | -50.72 Million USD | -64.308% |
| Immunovant, Inc. | -282.7 Million USD | 70.518% |
| Quantum-Si incorporated | -111.17 Million USD | 25.028% |
| Arbutus Biopharma Corporation | -78.1 Million USD | -6.714% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | -291.908% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 18.297% |
| Acasti Pharma Inc. | -11.31 Million USD | -636.802% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | -263.626% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | -421.592% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 61.063% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | -2171.61% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -424.657% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | -185.856% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | -101.399% |
| PepGen Inc. | -84.76 Million USD | 1.674% |
| Moleculin Biotech, Inc. | -29.63 Million USD | -181.283% |
| United Therapeutics Corporation | 1.18 Billion USD | 107.034% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -264.008% |
| Solid Biosciences Inc. | -104.31 Million USD | 20.101% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | -154.044% |
| Immuneering Corporation | -58.41 Million USD | -42.686% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -1537.39% |
| Silo Pharma, Inc. | -3.85 Million USD | -2061.717% |
| Belite Bio, Inc | -31.66 Million USD | -163.19% |
| XOMA Corporation | -41.84 Million USD | -99.166% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | -23.44% |
| Bionomics Limited | -17.89 Billion USD | 99.534% |
| Apogee Therapeutics, Inc. | -93 Million USD | 10.382% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 333.596% |
| uniQure N.V. | -282.87 Million USD | 70.535% |
| Cassava Sciences, Inc. | -105.95 Million USD | 21.339% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -1040.163% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 35.641% |
| Forte Biosciences, Inc. | -32.48 Million USD | -156.563% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | -903.123% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | -183.541% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -1398.508% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | -486.538% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | -837.642% |
| Altimmune, Inc. | -95.92 Million USD | 13.116% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -13.407% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 333.596% |
| Compugen Ltd. | -12.99 Million USD | -541.526% |
| Peak Bio, Inc. | -1356.23 USD | -6145391.546% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | -68.025% |
| Benitec Biopharma Inc. | -22.49 Million USD | -270.596% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 65.602% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | -180.196% |
| Zura Bio Limited | -62.63 Million USD | -33.061% |
| PolyPid Ltd. | -22.86 Million USD | -264.486% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | -412.085% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | -180.196% |
| Instil Bio, Inc. | -159.16 Million USD | 47.636% |
| argenx SE | -425.04 Million USD | 80.391% |
| Immunome, Inc. | -109.53 Million USD | 23.905% |
| Compass Therapeutics, Inc. | -50.36 Million USD | -65.493% |
| Verona Pharma plc | -67.83 Million USD | -22.875% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | -219.827% |
| Shattuck Labs, Inc. | -91.95 Million USD | 9.363% |
| CervoMed Inc. | -7.81 Million USD | -966.788% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | -14.002% |
| Plus Therapeutics, Inc. | -13.32 Million USD | -525.681% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | -73.012% |
| Moolec Science SA | -6.65 Million USD | -1152.622% |
| Enveric Biosciences, Inc. | -16.44 Million USD | -406.717% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 38.365% |
| AnaptysBio, Inc. | -164.41 Million USD | 49.306% |
| Design Therapeutics, Inc. | -78.19 Million USD | -6.595% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 4.244% |
| NeurAxis, Inc. | -6.66 Million USD | -1150.612% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | -105.8% |
| Lumos Pharma, Inc. | -36.61 Million USD | -127.637% |
| Achilles Therapeutics plc | -75.25 Million USD | -10.753% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | -219.827% |
| 180 Life Sciences Corp. | -13.47 Million USD | -518.416% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | 1716.408% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -2741.712% |
| Nutriband Inc. | -4.87 Million USD | -1610.761% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 24.763% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | -50.313% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | -63.953% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | -26.094% |
| MoonLake Immunotherapeutics | -54.12 Million USD | -53.995% |
| Palisade Bio, Inc. | -13.07 Million USD | -537.697% |
| Tourmaline Bio, Inc. | -45.4 Million USD | -83.547% |
| Beam Therapeutics Inc. | -176.48 Million USD | 52.774% |
| Neurogene Inc. | -55.58 Million USD | -49.951% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 23.643% |
| AEON Biopharma, Inc. | -48.42 Million USD | -72.101% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 13.818% |
| Sesen Bio, Inc. | -25.9 Million USD | -221.691% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 0.218% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | -562.173% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 81.903% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | -15.058% |
| Athira Pharma, Inc. | -125.46 Million USD | 33.57% |
| Vaccinex, Inc. | -22.88 Million USD | -264.199% |
| HCW Biologics Inc. | -25.71 Million USD | -224.091% |
| XOMA Corporation | -41.84 Million USD | -99.166% |
| Nektar Therapeutics | -137.42 Million USD | 39.351% |
| Arvinas, Inc. | -401.5 Million USD | 79.241% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -942416.309% |
| Merus N.V. | -156.54 Million USD | 46.759% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 16.87% |
| Quince Therapeutics, Inc. | -34.62 Million USD | -140.748% |
| Rezolute, Inc. | -70.42 Million USD | -18.352% |
| Clene Inc. | -40.54 Million USD | -105.592% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | -408.881% |
| BeyondSpring Inc. | -23.11 Million USD | -260.591% |
| Synlogic, Inc. | -55.16 Million USD | -51.098% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | -364.873% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -670.02% |
| Peak Bio, Inc. | -1356.23 USD | -6145391.546% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | -105.78% |
| Krystal Biotech, Inc. | -109.72 Million USD | 24.041% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 35.659% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 75.702% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | -1656.17% |
| MannKind Corporation | 8.67 Million USD | 1060.44% |
| Ikena Oncology, Inc. | -75.41 Million USD | -10.515% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | -763.968% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | -23.973% |
| Gossamer Bio, Inc. | -183.75 Million USD | 54.643% |
| CohBar, Inc. | -12.38 Million USD | -572.788% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | -64.315% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | -202.124% |
| Legend Biotech Corporation | -439.48 Million USD | 81.035% |
| Mural Oncology plc | -194.63 Million USD | 57.178% |
| Biora Therapeutics, Inc. | -67.14 Million USD | -24.134% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -416.232% |
| Disc Medicine, Inc. | -91.12 Million USD | 8.536% |
| Champions Oncology, Inc. | -7.35 Million USD | -1033.048% |
| REGENXBIO Inc. | -268.12 Million USD | 68.915% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -677.622% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -49.485% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | -113.926% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 27.117% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | -878.25% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | -94.763% |
| Cellectis S.A. | -106.62 Million USD | 21.832% |
| Longeveron Inc. | -21.02 Million USD | -296.343% |
| Repare Therapeutics Inc. | -116.22 Million USD | 28.288% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 68.88% |
| Inozyme Pharma, Inc. | -75.64 Million USD | -10.182% |
| Revolution Medicines, Inc. | -487.18 Million USD | 82.892% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | -1152.962% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | -89.623% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | -11.74% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | -19.691% |
| Anixa Biosciences, Inc. | -11.01 Million USD | -656.943% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 101.935% |
| Denali Therapeutics Inc. | -196.69 Million USD | 57.627% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -862.807% |
| Veru Inc. | -93.78 Million USD | 11.127% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | -257.268% |
| Cingulate Inc. | -22.75 Million USD | -266.213% |
| Passage Bio, Inc. | -108.38 Million USD | 23.104% |
| Context Therapeutics Inc. | -25.07 Million USD | -232.422% |
| Exicure, Inc. | -14.99 Million USD | -455.795% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 59.553% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | -105.298% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | -757.75% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 54.79% |
| Nuvalent, Inc. | -149.49 Million USD | 44.247% |
| ABVC BioPharma, Inc. | -8.21 Million USD | -914.385% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 6.068% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | -301.208% |
| OmniAb, Inc. | -69.41 Million USD | -20.064% |
| Anew Medical, Inc. | -1.3 Million USD | -6307.168% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | -552.627% |
| Lipocine Inc. | -17.93 Million USD | -364.822% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | -21.651% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | -9.448% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | -118.9% |
| G1 Therapeutics, Inc. | -39.52 Million USD | -110.861% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | -272.351% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 85.626% |
| Ocugen, Inc. | -65.53 Million USD | -27.187% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 11.206% |
| Q32 Bio Inc. | -92.1 Million USD | 9.506% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | -288.763% |
| Alumis Inc. Common Stock | -158.17 Million USD | 47.307% |
| Equillium, Inc. | -14.52 Million USD | -473.936% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | -33.556% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -954.578% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -341.805% |
| Galera Therapeutics, Inc. | -46.95 Million USD | -77.519% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 23.158% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -596.298% |
| Dominari Holdings Inc. | -21.79 Million USD | -282.396% |
| Edesa Biotech, Inc. | -9.22 Million USD | -803.71% |
| vTv Therapeutics Inc. | -25.5 Million USD | -226.825% |
| Bio-Techne Corporation | 206.68 Million USD | 140.325% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 78.71% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 143.403% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 36.991% |
| Candel Therapeutics, Inc. | -38.39 Million USD | -117.1% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 44.84% |
| Nkarta, Inc. | -131.65 Million USD | 36.69% |
| BioCardia, Inc. | -11.64 Million USD | -615.794% |
| Iterum Therapeutics plc | -47.46 Million USD | -75.586% |